Article Text

Download PDFPDF
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All authors have contributed to this manuscript and fulfil the requirements for authorship.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JA reports personal fees from Sanofi, Abbvie, Boerhinger, Nordic, Novartis, and grants and personal fees from Bristol Myers Squibb, Pfizer outside the submitted work; PA and NC have nothing to disclose. MM-C reports grant and personal fees from Actelion, Biogen, Bayer, Boehringer Ingelheim, CSL Behring and Eli-Lilly, outside the submitted work. YA reports personal fees from Actelion, Bayer, BMS, Boehringer Ingelheim and Curzion, and grants and personal fees from Inventiva, Roche and Sanofi.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles